References
- Hiraoka A. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogenic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181-5. https://doi.org/10.1038/sj.bmt.1703097
- Ferarra JL. Advances in the clinical management of GVHD. Best Pract Res Clin Haematol 2008; 21: 677-82. https://doi.org/10.1016/j.beha.2008.07.003
- Fay JW, Wingard JR, Antin JH, et al., FK506 (Tacrolimus) monotherapy for prevention of Graft-Versus-Host Disease After Histocompatible Sibling Allogenic Bone Marrow Transplantation. Blood 1996; 87: 3514-9.
- Arai S, Vogelsang GB. Management of graft-versus-host disease. Blood Rev 2000; 14: 190-204. https://doi.org/10.1054/blre.2000.0137
- Simpson D. Drug therapy for acute graft-versus-host disease prophylaxis. J Hemato Ther Stem Cell Res 2000; 9: 317-25. https://doi.org/10.1089/15258160050079425
- Lesley S. Tacrolimus, A further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247-97. https://doi.org/10.2165/00003495-200363120-00006
- Yanada M. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant 2004; 34: 331-7. https://doi.org/10.1038/sj.bmt.1704596
- Park K. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. Clin Ther 2007; 29: 154-62. https://doi.org/10.1016/j.clinthera.2007.01.016
- Jusko WJ, Thomson AW, Fung J, et al., Consensus document: therapeutic drug monitoring of tacrolimus (FK-506). Ther Drug Monit 1995; 17: 606-14. https://doi.org/10.1097/00007691-199512000-00011
- Staatz CE, Willis C, Taylor PJ, et al., Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin pharmacol Ther 2002; 72: 660-9. https://doi.org/10.1067/mcp.2002.129304
- Scott LJ, McKeage K, Keam SJ, et al., Taclorimus: A further update of its use in the management organ transplantation. Drugs 2003; 63: 1247-97. https://doi.org/10.2165/00003495-200363120-00006
- Felipe CR, Silva HT, Machado PG, et al., The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics ad therapeutic drug monitoring. Clin Transplant 2002; 16: 262-72. https://doi.org/10.1034/j.1399-0012.2002.01103.x
- Bekersky I, Dressler D, Alak A, et al., Comparative tacrolimus pharmacokinetics: Normal versus midly hepatically impaired subjects. J Clin Pharmacol 2001; 41: 628-35. https://doi.org/10.1177/00912700122010519
- Gaston S. Maintenance immunosuppression in the renal transplant recipient. An overview. Am J Kidney Dis 2001; 38: S25-S35. https://doi.org/10.1053/ajkd.2001.28923
- Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens 2003; 11: 657-63.
- Jusko WJ, Piekoszewski W, Klintmalm GB, et al., Pharmacokinetics and of tacrolimus in liver transplant patients. Clin pharmacol Ther 1995; 57: 281-90. https://doi.org/10.1016/0009-9236(95)90153-1
- Mekki Q, Lee C, Aweeka F, et al., pharmacokinetics of tacrolimus (FK506) in kidney transplant patients. Clin Pharmacol Ther 1993; 53: 238.
- Rowland M, Tozer T. Clinical pharmacokinetics: Concepts and applications. 3rd ed. Baltimore, Williams & Willkins, 1995; 290-309, 313-339.
- Boswell GW, Bekersky I, Fay J, et al., Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant 1998; 21: 23-8. https://doi.org/10.1038/sj.bmt.1701054
- Quan D, Winter ME. Immunosuppressants: Cyclosporine, tacrolimus, and sirolimus, In: Basic clinical pharmacokinetics. 4th ed. Baltimore, MD, Lippincortt Williams & Wilkins, 2004: 228-250.
- Cattanneo D, Perico N, RemuzzinG. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive. Am J Transplant 2004; 4: 299-310. https://doi.org/10.1111/j.1600-6143.2004.00312.x
- Yagil Y, Yagil C. Pharmacogenomic considerations for immunosuppressive therapy. Pharmacogenomics 2003; 4: 309-13. https://doi.org/10.1517/phgs.4.3.309.22690
- Weinshilboum R. Inheritance and drug response. New Eng J Med 2003; 348: 529-37. https://doi.org/10.1056/NEJMra020021
- Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets and side effects. New Eng J Med 2003; 348: 538-49. https://doi.org/10.1056/NEJMra020526
- MacPhee IA, Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and p-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-9. https://doi.org/10.1097/00007890-200212150-00002